No Consistent Antidepressant Effects of Deep Brain Stimulation of the Bed Nucleus of the Stria Terminalis.

bed nucleus of the stria terminalis clinical response deep brain stimulation major depression treatment resistance

Journal

Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646

Informations de publication

Date de publication:
15 May 2024
Historique:
received: 21 04 2024
revised: 06 05 2024
accepted: 07 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 25 5 2024
Statut: epublish

Résumé

Applying deep brain stimulation (DBS) to several brain regions has been investigated in attempts to treat highly treatment-resistant depression, with variable results. Our initial pilot data suggested that the bed nucleus of the stria terminalis (BNST) could be a promising therapeutic target. The aim of this study was to gather blinded data exploring the efficacy of applying DBS to the BNST in patients with highly refractory depression. Eight patients with chronic severe treatment-resistant depression underwent DBS to the BNST. A randomised, double-blind crossover study design with fixed stimulation parameters was followed and followed by a period of open-label stimulation. During the double-blind crossover phase, no consistent antidepressant effects were seen with any of the four stimulation parameters applied, and no patients achieved response or remission criteria during the blinded crossover phase or during a subsequent period of three months of blinded stimulation. Stimulation-related side effects, especially agitation, were reported by a number of patients and were reversible with adjustment of the stimulation parameters. The results of this study do not support the application of DBS to the BNST in patients with highly resistant depression or ongoing research utilising stimulation at this brain site. The blocked randomised study design utilising fixed stimulation parameters was poorly tolerated by the participants and does not appear suitable for assessing the efficacy of DBS at this location.

Sections du résumé

BACKGROUND BACKGROUND
Applying deep brain stimulation (DBS) to several brain regions has been investigated in attempts to treat highly treatment-resistant depression, with variable results. Our initial pilot data suggested that the bed nucleus of the stria terminalis (BNST) could be a promising therapeutic target.
OBJECTIVE OBJECTIVE
The aim of this study was to gather blinded data exploring the efficacy of applying DBS to the BNST in patients with highly refractory depression.
METHOD METHODS
Eight patients with chronic severe treatment-resistant depression underwent DBS to the BNST. A randomised, double-blind crossover study design with fixed stimulation parameters was followed and followed by a period of open-label stimulation.
RESULTS RESULTS
During the double-blind crossover phase, no consistent antidepressant effects were seen with any of the four stimulation parameters applied, and no patients achieved response or remission criteria during the blinded crossover phase or during a subsequent period of three months of blinded stimulation. Stimulation-related side effects, especially agitation, were reported by a number of patients and were reversible with adjustment of the stimulation parameters.
CONCLUSIONS CONCLUSIONS
The results of this study do not support the application of DBS to the BNST in patients with highly resistant depression or ongoing research utilising stimulation at this brain site. The blocked randomised study design utilising fixed stimulation parameters was poorly tolerated by the participants and does not appear suitable for assessing the efficacy of DBS at this location.

Identifiants

pubmed: 38790480
pii: brainsci14050499
doi: 10.3390/brainsci14050499
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Health and Medical Research Council
ID : 1077859

Auteurs

Paul B Fitzgerald (PB)

School of Medicine and Psychology, Australian National University, Canberra, ACT 2601, Australia.

Kate Hoy (K)

Bionics Institute of Australia, East Melbourne, Melbourne, VIC 3002, Australia.

Karyn E Richardson (KE)

BrainPark, Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC 3168, Australia.

Kirsten Gainsford (K)

School of Medicine and Psychology, Australian National University, Canberra, ACT 2601, Australia.

Rebecca Segrave (R)

BrainPark, Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC 3168, Australia.
Monash Biomedical Imaging, Monash University, Clayton, VIC 3168, Australia.

Sally E Herring (SE)

Bionics Institute of Australia, East Melbourne, Melbourne, VIC 3002, Australia.

Zafiris J Daskalakis (ZJ)

Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA.

Richard G Bittar (RG)

Precision Brain Spine and Pain Centre, Melbourne, VIC 3109, Australia.
Faculty of Health, Deakin University, Melbourne, VIC 3000, Australia.

Classifications MeSH